Which has preferable valuation and earnings, GILD or AMGN?

Gilead Sciences has higher earnings, but lower revenue than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44B 5.54 $8.51B $7.34 17.88 Amgen $36.75B 5.49 $7.71B $14.37 26.04

Is GILD or AMGN more profitable?

Gilead Sciences has a net margin of 30.99% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences 30.99% 48.19% 18.28% Amgen 20.96% 137.41% 13.28%

Does the media prefer GILD or AMGN?

In the previous week, Amgen had 7 more articles in the media than Gilead Sciences. MarketBeat recorded 33 mentions for Amgen and 26 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.41 beat Amgen's score of 1.01 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 21 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 26 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to LGND or GILD?

In the previous week, Gilead Sciences had 21 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 26 mentions for Gilead Sciences and 5 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.41 beat Ligand Pharmaceuticals' score of 0.98 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 21 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, MRNA or GILD?

Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 16.28 -$2.82B -$8.15 N/A Gilead Sciences $29.44B 5.54 $8.51B $7.34 17.88

Is MRNA or GILD more profitable?

Gilead Sciences has a net margin of 30.99% compared to Moderna's net margin of -143.55%. Gilead Sciences' return on equity of 48.19% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Gilead Sciences 30.99% 48.19% 18.28%

Does the media refer more to MRNA or GILD?

In the previous week, Gilead Sciences had 9 more articles in the media than Moderna. MarketBeat recorded 26 mentions for Gilead Sciences and 17 mentions for Moderna. Gilead Sciences' average media sentiment score of 1.41 beat Moderna's score of 0.55 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 5 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 21 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor REGN or GILD?

In the previous week, Gilead Sciences had 13 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 26 mentions for Gilead Sciences and 13 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.41 beat Regeneron Pharmaceuticals' score of 1.29 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 21 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VIR or GILD?

In the previous week, Gilead Sciences had 24 more articles in the media than Vir Biotechnology. MarketBeat recorded 26 mentions for Gilead Sciences and 2 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 1.41 beat Vir Biotechnology's score of 1.24 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 21 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gilead Sciences (GILD) Competitors

$131.27 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$132.78 +1.51 (+1.15%)

As of 05:17 AM Eastern

Compare

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

Should you buy Gilead Sciences stock or one of its competitors? MarketBeat compares Gilead Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gilead Sciences include Amgen (AMGN), Ligand Pharmaceuticals (LGND), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), and Vir Biotechnology (VIR). These companies are all part of the "med - biomed/gene" industry.

How does Gilead Sciences compare to Amgen?

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.7%. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Amgen had 7 more articles in the media than Gilead Sciences. MarketBeat recorded 33 mentions for Amgen and 26 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.41 beat Amgen's score of 1.01 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	21 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	26 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Gilead Sciences has higher earnings, but lower revenue than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.88
Amgen	$36.75B	5.49	$7.71B	$14.37	26.04

Gilead Sciences presently has a consensus target price of $158.41, suggesting a potential upside of 20.67%. Amgen has a consensus target price of $355.50, suggesting a potential downside of 4.98%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

Gilead Sciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Gilead Sciences has a net margin of 30.99% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Amgen	20.96%	137.41%	13.28%

Summary

Gilead Sciences and Amgen tied by winning 10 of the 20 factors compared between the two stocks.

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Ligand Pharmaceuticals presently has a consensus price target of $257.71, suggesting a potential downside of 19.35%. Gilead Sciences has a consensus price target of $158.41, suggesting a potential upside of 20.67%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Ligand Pharmaceuticals has a net margin of 55.95% compared to Gilead Sciences' net margin of 30.99%. Gilead Sciences' return on equity of 48.19% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Gilead Sciences	30.99%	48.19%	18.28%

Gilead Sciences has higher revenue and earnings than Ligand Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.89	$124.45M	$7.37	43.36
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.88

Ligand Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

In the previous week, Gilead Sciences had 21 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 26 mentions for Gilead Sciences and 5 mentions for Ligand Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.41 beat Ligand Pharmaceuticals' score of 0.98 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	21 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Ligand Pharmaceuticals and Gilead Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Gilead Sciences compare to Moderna?

Moderna (NASDAQ:MRNA) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	16.28	-$2.82B	-$8.15	N/A
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.88

Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gilead Sciences has a net margin of 30.99% compared to Moderna's net margin of -143.55%. Gilead Sciences' return on equity of 48.19% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Gilead Sciences	30.99%	48.19%	18.28%

Moderna presently has a consensus price target of $37.13, suggesting a potential downside of 53.44%. Gilead Sciences has a consensus price target of $158.41, suggesting a potential upside of 20.67%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Gilead Sciences had 9 more articles in the media than Moderna. MarketBeat recorded 26 mentions for Gilead Sciences and 17 mentions for Moderna. Gilead Sciences' average media sentiment score of 1.41 beat Moderna's score of 0.55 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	5 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	21 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gilead Sciences beats Moderna on 13 of the 16 factors compared between the two stocks.

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Regeneron Pharmaceuticals has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.6%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.5%. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a net margin of 30.99% compared to Regeneron Pharmaceuticals' net margin of 29.65%. Gilead Sciences' return on equity of 48.19% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Gilead Sciences	30.99%	48.19%	18.28%

In the previous week, Gilead Sciences had 13 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 26 mentions for Gilead Sciences and 13 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.41 beat Regeneron Pharmaceuticals' score of 1.29 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	12 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	21 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals presently has a consensus price target of $792.65, suggesting a potential upside of 21.15%. Gilead Sciences has a consensus price target of $158.41, suggesting a potential upside of 20.67%. Given Regeneron Pharmaceuticals' higher probable upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.73
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.82	$4.50B	$41.04	15.94
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.88

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 15 of the 20 factors compared between the two stocks.

How does Gilead Sciences compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Vir Biotechnology presently has a consensus target price of $20.88, suggesting a potential upside of 107.92%. Gilead Sciences has a consensus target price of $158.41, suggesting a potential upside of 20.67%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, equities analysts clearly believe Vir Biotechnology is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Vir Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	24.70	-$437.99M	-$3.13	N/A
Gilead Sciences	$29.44B	5.54	$8.51B	$7.34	17.88

Gilead Sciences has a net margin of 30.99% compared to Vir Biotechnology's net margin of -638.88%. Gilead Sciences' return on equity of 48.19% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-53.31%	-41.76%
Gilead Sciences	30.99%	48.19%	18.28%

In the previous week, Gilead Sciences had 24 more articles in the media than Vir Biotechnology. MarketBeat recorded 26 mentions for Gilead Sciences and 2 mentions for Vir Biotechnology. Gilead Sciences' average media sentiment score of 1.41 beat Vir Biotechnology's score of 1.24 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	21 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Gilead Sciences beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.

Get Gilead Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GILD vs. The Competition

Export

Metric	Gilead Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$162.98B	$3.76B	$6.98B	$12.46B
Dividend Yield	2.50%	2.16%	2.66%	6.52%
P/E Ratio	17.88	21.80	27.80	24.70
Price / Sales	5.54	326.25	535.80	98.72
Price / Cash	12.54	64.18	29.65	49.23
Price / Book	7.20	8.67	10.87	6.49
Net Income	$8.51B	$23.68M	$3.57B	$336.25M
7 Day Performance	3.91%	1.23%	1.14%	0.35%
1 Month Performance	1.63%	13.43%	6.07%	3.91%
1 Year Performance	17.97%	62.61%	33.30%	23.88%

Gilead Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GILD Gilead Sciences	4.971 of 5 stars	$131.27 flat	$159.22 +21.3%	+18.0%	$162.98B	$29.44B	17.88	17,000	Positive News Gap Down
AMGN Amgen	3.9152 of 5 stars	$360.55 +0.6%	$354.42 -1.7%	+25.4%	$194.59B	$36.75B	25.09	31,500	Positive News Gap Down
LGND Ligand Pharmaceuticals	2.6412 of 5 stars	$314.04 +3.4%	$257.71 -17.9%	+179.4%	$6.29B	$268.09M	42.61	80	High Trading Volume
MRNA Moderna	1.1591 of 5 stars	$69.70 +3.6%	$37.13 -46.7%	+161.8%	$27.66B	$1.94B	N/A	4,700	Gap Down
REGN Regeneron Pharmaceuticals	4.8599 of 5 stars	$631.81 -0.2%	$792.65 +25.5%	+20.0%	$66.79B	$14.34B	15.39	15,410	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GILD) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Competitors

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

How does Gilead Sciences compare to Amgen?

Summary

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Summary

How does Gilead Sciences compare to Moderna?

Summary

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Summary

How does Gilead Sciences compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD vs. The Competition

Gilead Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gilead Sciences (GILD) Competitors

GILD vs. AMGN, LGND, MRNA, REGN, and VIR

How does Gilead Sciences compare to Amgen?

Is GILD or AMGN a better dividend stock?

Do institutionals & insiders have more ownership in GILD or AMGN?

Does the media prefer GILD or AMGN?

Which has preferable valuation and earnings, GILD or AMGN?

Do analysts prefer GILD or AMGN?

Which has more risk & volatility, GILD or AMGN?

Is GILD or AMGN more profitable?

Summary

How does Gilead Sciences compare to Ligand Pharmaceuticals?

Do analysts recommend LGND or GILD?

Is LGND or GILD more profitable?

Which has stronger valuation and earnings, LGND or GILD?

Which has more risk and volatility, LGND or GILD?

Does the media refer more to LGND or GILD?

Do institutionals & insiders hold more shares of LGND or GILD?

Summary

How does Gilead Sciences compare to Moderna?

Which has higher valuation and earnings, MRNA or GILD?

Which has more volatility and risk, MRNA or GILD?

Do institutionals & insiders have more ownership in MRNA or GILD?

Is MRNA or GILD more profitable?

Do analysts rate MRNA or GILD?

Does the media refer more to MRNA or GILD?

Summary

How does Gilead Sciences compare to Regeneron Pharmaceuticals?

Which has more risk and volatility, REGN or GILD?

Do institutionals & insiders have more ownership in REGN or GILD?

Is REGN or GILD a better dividend stock?

Is REGN or GILD more profitable?

Does the media favor REGN or GILD?

Do analysts rate REGN or GILD?

Which has preferable earnings & valuation, REGN or GILD?

Summary

How does Gilead Sciences compare to Vir Biotechnology?

Do analysts rate VIR or GILD?

Which has more risk and volatility, VIR or GILD?

Which has better earnings and valuation, VIR or GILD?

Is VIR or GILD more profitable?

Does the media refer more to VIR or GILD?

Do insiders and institutionals hold more shares of VIR or GILD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GILD vs. The Competition

Gilead Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools